Squamous cell carcinoma of the skin: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 144: Line 144:
*'''[[Squamous cell carcinoma medical treatment|Medical treatment]]'''
*'''[[Squamous cell carcinoma medical treatment|Medical treatment]]'''
*'''[[Squamous cell carcinoma surgical treatment|Surgical treatment]]'''
*'''[[Squamous cell carcinoma surgical treatment|Surgical treatment]]'''
*'''[[Primary Prevention]]'''


==Future and Investigational treatment strategies==
==Future and Investigational treatment strategies==

Revision as of 15:19, 14 June 2012

For patient information click here

Template:DiseaseDisorder infobox

Squamous cell carcinoma of the skin Microchapters

Home

Patient Info

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Squamous cell carcinoma of the skin from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT Scan

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Squamous cell carcinoma of the skin On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Squamous cell carcinoma of the skin

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Squamous cell carcinoma of the skin

CDC on Squamous cell carcinoma of the skin

Squamous cell carcinoma of the skin in the news

Blogs on Squamous cell carcinoma of the skin

Directions to Hospitals Treating Squamous cell carcinoma of the skin

Risk calculators and risk factors for Squamous cell carcinoma of the skin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2], Raviteja Guddeti, M.B.B.S. [3]

Overview

Historical Aspects

Pathophysiology

Epidemiology and Demographics

Risk Factors

Screening

Causes of Squamous cell carcinoma

Differential Diagnosis

Natural History Complications and Prognosis

Clinical Features

Diagnosis

Diagnosis is via a biopsy. For the skin, look under skin biopsy.

The pathological appearance of a squamous cell cancer varies with the depth of the biopsy. For that reason, a biopsy including the subcutanous tissue and basalar epithelium, to the surface is necessary for correct diagnosis. The performance of a shave biopsy (see skin biopsy) might not acquire enough information for a diagnosis. An excision biopsy is ideal, but not practical in most cases. An incisional or punch biopsy is preferred. A shave biopsy is least ideal, especially if only the superficial portion is acquired.

Physical Examination

Skin

Squamous cell carcinoma of the skin is often caused by long term exposure to the sun. To be diagnosed, a biopsy is done where a sample is taken and examined under a microscope by a Pathologist. If it is found to be cancerous, a surgery is done to remove it.

Squamous cell carcinomas account for about 20% of non-melanoma skin cancers, (with basal cell carcinomas accounting for about 80%), and are clinically more significant because of their ability to metastasize. Squamous cell carcinoma is usually developed in the epithelial layer of the skin and sometimes in various mucous membranes of the body.

Squamous cell carcinoma is the second most common cancer of the skin (after basal cell carcinoma but more common than melanoma). It usually occurs in areas exposed to the sun, and can generally be treated by excision or mohs surgery only.

Sunlight exposure and immunosuppression are risk factors for SCC of the skin with chronic sun exposure being the strongest environmental risk factor.[1] The risk of metastasis is low, but is much higher than basal cell carcinoma.

Squamous cell cancers of the lip and ears have high metastatic and recurrence rate (20 to 50%)[2]. Squamous cell cancers of the skin in individuals on immunotherapy or having lymphoproliferative disorders (leukemias) are much more aggressive, regardless of their location.[3]

Australian scientist Ian Frazer who developed the cervical cancer vaccine, says that animal tests have been effective in preventing squamous cell carcinoma in animals, and there may be a human vaccine against this kind of skin cancer within the decade.[4]

Ear Nose and Throat





Esophagus

Esophageal cancer may be due to either squamous cell carcinoma (ESCC) or adenocarcinoma (EAC). SCCs tend to occur closer to the mouth, while adenocarcinomas occur closer to the stomach. Dysphagia (difficulty swallowing, solids worse than liquids) and odynophagia are common initial symptoms. If the disease is localized, esophagectomy may offer the possibility of a cure. If the disease has spread, chemotherapy and radiotherapy are commonly used.

Penis

When squamous cell carcinoma in situ (Bowen's disease) is found on the penis, it is called erythroplasia of Queyrat[10]. This type of cancer respond very well to an experimental agent called Aldara.

Prostate

When associated with the prostate, squamous cell carcinoma is very aggressive in nature. It is difficult to detect as there is no increase in prostate specific antigen levels seen; meaning that the cancer is often diagnosed at an advanced stage.

Lung

When associated with the lung, it often causes ectopic production of parathyroid hormone-related protein (PTHrP), resulting in hypercalcemia.

Vagina and cervix

Vaginal squamous cell carcinoma spreads slowly and usually stays near the vagina, but may spread to the lungs and liver. This is the most common type of vaginal cancer.

Cervix: Squamous cell carcinoma

<youtube v=zB47nE-i8dQ/>


<youtube v=J3kULzKGzws/>


Treatment

Future and Investigational treatment strategies

In 2007, Australian biopharmaceutical company Clinuvel Pharmaceuticals Limited began clinical trials with a melanocyte-stimulating hormone called melanotan (known by the International Nonproprietary Name afamelanotide, formerly CUV1647)[11] to provide photoprotection for organ transplant patients against squamous cell carcinoma of the skin and actinic keratosis.[12][13]

Cetuximab a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), has antitumor activity in patients with advanced squamous cell carcinoma of the skin, as initially suggested by case reports.

References

  1. name="mdconsult"
  2. http://www.aad.org/public/publications/pamphlets/sun_squamous.html
  3. http://www.skincarephysicians.com/skincancernet/squamous_cell_carcinoma.html
  4. Cosmos Online - Skin cancer vaccine within reach (http://www.cosmosmagazine.com/news/2327/skin-cancer-vaccine-within-reach)
  5. http://picasaweb.google.com/mcmumbi/USMLEIIImages
  6. http://picasaweb.google.com/mcmumbi/USMLEIIImages
  7. http://www.ghorayeb.com
  8. http://www.ghorayeb.com
  9. http://www.ghorayeb.com
  10. http://www.emedicine.com/derm/TOPIC144.HTM
  11. "World Health Organisation assigns CUV1647 generic name" (PDF). Clinuvel. 2008. Retrieved 2008-06-17.
  12. Clinuvel » Investors » FAQs
  13. PharmaAsia - Clinuvel’s Drug Begins Global Phase II Skin Cancer Trials

External links


Template:Tumors of bone, cartilage, skin, connective, and soft tissue Template:Respiratory and intrathoracic neoplasia Template:Genital neoplasia Template:Epithelial neoplasms

de:Plattenepithelkarzinom he:קרצינומת תאי קשקש nl:Plaveiselcelcarcinoom


Template:WikiDoc Sources